Losing Positive Symptoms and Gaining Positive Outcomes in Schizophrenia

All Sessions Will Be Held in Eastern Time (ET)

From approval of a brand-new medication with a novel, non-dopaminergic mechanism of action to a more concerted effort to address negative and cognitive symptoms, recent advances in the treatment of schizophrenia bring promise of improved patient outcomes.

This half-day program will explore our evolution in understanding of the neurocircuitry hypothesized to underlie the various symptom domains of schizophrenia. With this updated knowledge, novel strategies to improve psychosis as well as negative and cognitive symptoms of schizophrenia (and thereby improve functional outcomes and quality of life for patients living with schizophrenia) will be discussed.



Saturday, February 28, 2026

Add to Cart

9:00 am - 10:00 am ET

Focus on Psychosis: Integrating Therapeutic Advances in the Treatment of Positive Symptoms of Schizophrenia

Christoph U. Correll

This CME/CE session will review evolving concepts in the neuropathology of positive symptoms, contrast traditional dopaminergic approaches with muscarinic modulation, and examine clinical evidence supporting xanomeline–trospium and other emerging muscarinic agents. Practical guidance will be provided on patient selection, transitioning from or combining with DRBAs, and managing cholinergic adverse effects to support safe and effective clinical implementation.

10:00 am - 11:00 am ET

Innovation Theater

Sponsored by AbbVie, Inc.

11:00 am - 11:05 am ET

Break

11:05 am - 12:05 pm ET

Focus on Prognosis: Strategies to Address Negative and Cognitive Symptoms and Improve Functional Outcomes and Quality of Life in Patients With Schizophrenia

Andrew J. Cutler

This CME/CE session will examine the clinical and prognostic impact of negative symptoms and cognitive impairment associated with schizophrenia (CIAS) and critically evaluate emerging pharmacologic and non-pharmacologic interventions targeting these domains. Learners will receive practical guidance on integrating pharmacologic advances, behavioral strategies, prescription digital therapeutics, and psychosocial supports to improve functional outcomes while strengthening the therapeutic alliance and patient engagement.

12:05 pm - 12:50 pm ET

Innovation Theater: Clinical Snapshot: Efficacy and Safety of an Adjunctive Therapy for Major Depressive Disorder

Sponsored by Johnson & Johnson

12:50 pm - 1:30 pm ET



The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.



Program Faculty

Christoph U. Correll, MD


Clinical Professor of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, NY

Professor of Child and Adolescent Psychiatry at Charité University Medicine, Berlin, Germany


Andrew J. Cutler, MD


Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University

Chief Medical Officer, Neuroscience Education Institute, Malvern, PA



Explore Past Saturday Morning Live Sessions

Revisit, learn from, and enjoy recorded presentations from previous Saturday Morning Live events. Access expert-led sessions that offer practical, evidence-based insights to support your clinical work.

Encore Presentations provide 24/7 access to our on-demand library, giving you the flexibility to watch, learn, and earn credits anytime.


Start Watching